Ekwall O, Hedstrand H, Grimelius L, Haavik J, Perheentupa J, Gustafsson J, Husebye E, Kämpe O, Rorsman F
Department of Internal Medicine, University Hospital, Uppsala University, Sweden.
Lancet. 1998 Jul 25;352(9124):279-83. doi: 10.1016/S0140-6736(97)11050-9.
Autoimmune polyendocrine syndrome type 1 (APS1) is an autosomal recessive disorder with both endocrine and non-endocrine features. Periodic gastrointestinal dysfunction occurs in 25-30% of APS1 patients. We aimed to identify an intestinal autoantigen.
A human duodenal cDNA library was immunoscreened with serum samples from APS1 patients. A positive clone was identified and used for in-vitro transcription and translation, followed by immunoprecipitation with serum samples from 80 APS1 patients from Norway, Finland, and Sweden. Sections of normal and APS1-affected small intestine were immunostained with serum from APS1 patients and specific antibodies. An enzyme-inhibition assay was used to characterise the autoantibodies.
We isolated a cDNA clone coding for tryptophan hydroxylase. 48% (38/80) of APS1 patients had antibodies to tryptophan hydroxylase, whereas no reactivity to this antigen was detected in patients with other autoimmune diseases (n=372) or healthy blood donors (n=70). 89% (17/19) of APS1 patients with gastrointestinal dysfunction were positive for antibodies to tryptophan hydroxylase, compared with 34% (21/61) of patients with no gastrointestinal dysfunction (p<0.0001). Serum from antibody-positive APS1 patients specifically immunostained tryptophan-hydroxylase-containing enterochromaffin cells in normal duodenal mucosa. No serotonin-containing cells were seen in duodenal biopsy samples from APS1 patients. Serum from antibody-positive APS1 patients almost completely inhibited activity of tryptophan hydroxylase.
Tryptophan hydroxylase is an endogenous intestinal autoantigen in APS1, and there is an association between antibodies to the antigen and gastrointestinal dysfunction. Analysis of antibodies to tryptophan hydroxylase may be a valuable diagnostic tool to predict and monitor gastrointestinal dysfunction in APS1.
1型自身免疫性多内分泌腺综合征(APS1)是一种常染色体隐性疾病,具有内分泌和非内分泌特征。25% - 30%的APS1患者会出现周期性胃肠功能障碍。我们旨在鉴定一种肠道自身抗原。
用人十二指肠cDNA文库对APS1患者的血清样本进行免疫筛选。鉴定出一个阳性克隆,并用于体外转录和翻译,随后用来自挪威、芬兰和瑞典的80例APS1患者的血清样本进行免疫沉淀。用APS1患者的血清和特异性抗体对正常和受APS1影响的小肠切片进行免疫染色。采用酶抑制试验对自身抗体进行表征。
我们分离出一个编码色氨酸羟化酶的cDNA克隆。48%(38/80)的APS1患者有色氨酸羟化酶抗体,而在其他自身免疫性疾病患者(n = 372)或健康献血者(n = 70)中未检测到对该抗原的反应性。89%(17/19)有胃肠功能障碍的APS1患者色氨酸羟化酶抗体呈阳性,而无胃肠功能障碍的患者中这一比例为34%(21/61)(p<0.0001)。抗体阳性的APS1患者血清特异性免疫染色正常十二指肠黏膜中含色氨酸羟化酶的肠嗜铬细胞。在APS1患者的十二指肠活检样本中未见含5-羟色胺的细胞。抗体阳性的APS1患者血清几乎完全抑制色氨酸羟化酶的活性。
色氨酸羟化酶是APS1中的一种内源性肠道自身抗原,该抗原的抗体与胃肠功能障碍之间存在关联。分析色氨酸羟化酶抗体可能是预测和监测APS1患者胃肠功能障碍的一种有价值的诊断工具。